Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
PD-1/L1
Biotech
Pfizer pays 3SBio $1.25B for PD-1xVEGF bispecific
Pfizer has bagged ex-China rights, establishing itself as a challenger to BioNTech, Merck and Summit in a scorching-hot area of immuno-oncology.
Nick Paul Taylor
May 20, 2025 4:47am
Will Novartis catch the PD-1 bispecific wave? CEO weighs in
Jan 31, 2025 3:30am
BioNTech posts overall survival data on would-be Keytruda killer
Dec 10, 2024 9:00am
Gilead and Arcus' TIGIT combo continues to show signs of life
Jun 3, 2023 1:30pm
Gut microbiota could hold key to why some cancer therapies fail
May 9, 2023 7:20am
Merck exec defends aggressive Keytruda prostate cancer program
Feb 16, 2023 6:30am
